Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

NCT05350917 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive or Mutated Advanced Colorectal Cancer

Interventions

DRUG: Tislelizumab

Sponsor

The First Affiliated Hospital of Zhengzhou University

Collaborators

[object Object]
[object Object]
[object Object]